24 results about "Heart dysfunction" patented technology

The invention discloses application of ADAMTS4 as a biomarker of sepsis with cardiac dysfunction, AUCROC is equal to 0.930, 95% CI is 0.859-1.000 in diagnosis of sepsis with cardiac dysfunction as the biomarker, accuracy is high, and a new detection means and scheme are provided for diagnosis and prediction of sepsis with cardiac dysfunction.

The application discloses a medicine for warming yang, promoting water excretion and detoxification, and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The medicine for warming yang, promoting water excretion and detoxification provided by the application takes prepared aconite, dried ginger and fried licorice as monarch drugs to stimulate the vital energy of the whole body and supplement yang qi of the heart, spleen and kidney; takes rhubarb and soapberry thorn as minister drugs to clear heat, detoxify and dredge the triple energizer; takes cassia twig and poria as auxiliary drugs to warm yang, promote the circulation of qi, reduce edema and promote water excretion; and takes taizishen as a minister drug to supplement qi, remove dampness and regulate qi movement. The whole prescription can supplement deficiency and eliminate excess, and has the functions of warming yang, detoxification and water excretion. The medicine can treat the root "deficiency of yang qi and invasion of pathogenic factors" of sepsis heart dysfunction, achieve the effect of treating the root and branch at the same time, reduce the inflammation level, cTnT and BNP level of a patient, and achieve the treatment of sepsis heart dysfunction.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

This invention discloses the application of GW3965 in the preparation of drugs that alleviate cardiac damage caused by doxorubicin. Experiments have demonstrated that GW3965 can, while inhibiting tumor growth, alleviate cardiac dysfunction related to doxorubicin cardiotoxicity, reduce doxorubicin-induced cardiac fibrosis, and inhibit doxorubicin-induced cardiomyocyte atrophy and apoptosis. This suggests that GW3965 can alleviate cardiac damage caused by doxorubicin, increase the safety of doxorubicin chemotherapy, and has promising clinical application prospects.

The application discloses a kind of drug for treating heart toxicity caused by VEGFR inhibitor with CXCL12 gene or protein as target point, belongs to medical technology field.The drug reverses heart toxicity caused by VEGFR inhibitor by down-regulating the expression of CXCL12 gene or the accumulation of CXCL12 protein in heart.Specifically, the application provides shRNA, neutralizing antibody or small molecule drug targeting CXCL12 as drug for reversing heart toxicity caused by VEGFR inhibitor.The application provides new intervention target and effective strategy for intervention of heart dysfunction caused by VEGFR inhibitor such as lefratinib, and provides feasible medication scheme for clinic.

The present invention is related to a composition comprising a novel chemical compound with the chemical Name "4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol" and its use. The 4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol and related compounds are useful for treating microgravity induced damage such as skeletal muscle atrophy and dysfunction as well as cardiac dysfunction and are also useful for human diseases and conditions accompanied by significant loss of muscle mass and reduced endurance capacity, such as immobilized patients, cancer, heart failure, sepsis, diabetes mellitus, muscle genetic diseases and neurodegenerative disorders. In addition, 4-(4-((4- Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2-isopropylphenol and related compounds are useful for treating human diseases related to muscle degeneration and ageing such as sarcopenia and heart failure.

The invention discloses application of cornua cervi pantotrichum tissue-derived exosome-like nanoparticles in preparation of a medicine for preventing and treating senile cardiovascular diseases. A sterile, stable and high-purity cornua cervi pantotrichum tissue exosome is obtained by adopting an enzyme digestion-differential centrifugation-ultra-high-speed centrifugation combined method, the physiological efficacy of the cornua cervi pantotrichum tissue exosome in heart protection is studied, and it is found that the cornua cervi pantotrichum tissue exosome can significantly improve cardiac dysfunction of acute aging mice induced by D-galactose (D-Gal). The cardiac ejection function, the cardiac fibrosis and the inflammation invasion level are remarkably improved. The compound has treatment potential in preparation of medicines for preventing heart protection and treating heart diseases, and provides a new strategy and a treatment method for treating cardiovascular diseases of old people.

The invention relates to an application of an Adtrp virus in preparation of a medicine for treating heart failure. The invention discloses a gene therapy method for treating heart failure based on a myoAAV1A-Adtrp virus vector. According to the present invention, the deficiency of the whole genome Adtrp causes the heart dysfunction and the heart failure, the deficiency of the Adtrp further aggravates the heart dysfunction and the heart failure, the results show that the deficiency of the Adtrp causes the heart failure, the myoAAV1A-Adtrp gene therapy can effectively block the heart failure development Lepr, Apob and Col7a1 of the heart failure CAD and TAC model, the expression levels of the adhesion molecules Icam-1, Vcam-1, E-selectin, P-selectin and p65 are changed, and the MyoAAV1A-Adtrp gene therapy can reverse the effect; adtrp plays an important role in the pathogenesis of heart failure, and the MyoAAV1A-Adtrp gene is used for treating the heart failure, so that the heart dysfunction and the heart failure of CAD and TAC models can be obviously relieved.

The present invention discloses an application of TREM2hi macrophages in preparation of drugs for treating cardiac dysfunction, and belongs to the technical field of medicine. The present invention discloses for the first time that there is a kind of macrophage subsets for high expression of a triggering receptor expressed on myeloid cells-2 in cardiac derived macrophages, which has a strong function of recognizing and reducing mitochondrial damage and plays an important role in maintaining a cardiac metabolic balance. Therefore, the TREM2hi macrophages have important application value in treatment of the cardiac dysfunction.

Introduced here approaches to developing, training, and implementing algorithms to cardiac dysfunction through automated analysis of physiological data. As an example, a model may be developed and then trained to quantify left and right ventricular dysfunction using electrocardiogram waveform data that is associated with a population of individuals who are diverse in terms of age, gender, ethnicity, socioeconomic status, and the like. This approach to training allows the model to predict the presence of left and right ventricular dysfunction in a diverse population. Also introduced here is a regression framework for predicting numeric values of left ventricular ejection fraction.

The application discloses an early evaluation system for diastolic heart dysfunction, and relates to the technical field of medical treatment. IVR and SR E ; a storage module is used for storing the normal reference ranges of SR IVR and SR E of healthy people in different age groups; an evaluation output module is used for comparing the SR IVR and SRE of the examinee with the normal reference ranges in the storage module, and outputting the early evaluation result of the diastolic heart dysfunction; the secondary screening is conducted on the hypertensive patients who cannot be diagnosed as having the diastolic heart dysfunction through the conventional ultrasound, so that the basis for early intervention is provided, and the incidence of the diastolic heart failure can be reduced.

The application belongs to the technical field of biological medicine, and specifically discloses a new use of Areg. The application discloses the following: a preparation for promoting expression of Areg or Areg protein is used for preparing a drug for preventing and treating myocardial infarction; the preparation for promoting expression of Areg or Areg protein is used for preparing a drug for preventing and treating heart dysfunction; a preparation for inhibiting expression of Areg is used for preparing a biological model of myocardial infarction or a biological model of adverse ventricular remodeling; a preparation for detecting expression level of Areg is used for preparing a product for screening (diagnosing) myocardial infarction. It is found that expression of Areg protein is increased after myocardial infarction of a mouse, and it is found that knocking out Areg can aggravate adverse ventricular remodeling after myocardial infarction of a mouse. It is verified that by increasing expression level of Areg protein, autophagosome formation is inhibited, myocardial cell apoptosis is reduced, loss of functional myocardial cells is reduced, thereby ventricular remodeling is improved, and heart function is protected.

The application belongs to the technical field of biological medicine and treatment of cardiovascular and cerebrovascular diseases, and particularly relates to application of alpha-ketoglutarate in preparation of a medicine for improving diabetic cardiomyopathy, and the alpha-ketoglutarate can reduce hyperglycemia and hyperlipidemia, improve insulin resistance and cardiac dysfunction caused by hyperglycemia and insulin resistance, for example, significant reduction of fasting blood glucose insulin and blood lipids, and significant improvement of glucose tolerance and insulin resistance; meanwhile, the alpha-ketoglutarate can effectively improve cardiac systolic dysfunction caused by diabetic cardiomyopathy, and reduce the degree of myocardial tissue pathological damage and fibrosis. The alpha-ketoglutarate is used for the treatment of diabetic cardiomyopathy for the first time, and important basis is provided for using the alpha-ketoglutarate to treat diabetic cardiomyopathy in clinic.

The present invention pertains to a peptide of the S100A1 protein for use in the treatment or prevention of antineoplastic agent-mediated cytotoxicity or cancer therapy-related cardiac dysfunction (CTRCD) or cancer therapy-related heart failure (CTRHF), as well as nucleic acids encoding said peptide, vectors comprising said nucleic acid, host cells comprising the vector or nucleic acid and expressing it, and to respective pharmaceutical compositions.

The invention belongs to the field of biological medicines, and particularly relates to application of astragaloside in preparation of a medicine for treating myocardial remodeling after myocardial infarction. In-vivo and in-vitro experiments prove that the astragaloside can up-regulate the expression of Acox1, Cd36, Pgc1a and Cpt1a lipid metabolism related factors and improve lipid metabolism disorder after myocardial infarction; meanwhile, Acta2, Col1a1, Col3a1, Postn fibrosis factors and alpha-SMA expression are inhibited, and myocardial fibrosis after myocardial infarction is relieved; the left ventricular ejection fraction and the left ventricular short axis shortening rate can be remarkably increased, the left ventricular end diastolic inner diameter and the left ventricular end systolic inner diameter are reduced, and cardiac dysfunction caused by myocardial infarction is improved. The composition can block pathological circulation of lipid metabolism disorder, myocardial fibrosis and cardiac function decline in a targeted manner, the curative effect is dose-dependent, the safety is good, and a brand new effective drug choice is provided for clinical treatment of myocardial remodeling after myocardial infarction.

The present invention relates to a composition comprising bindarit for preventing, alleviating or treating heart disease. The composition promotes survival and proliferation of endothelial cells and regulates cell stress and apoptosis, and thus has an effect of preventing, alleviating or treating heart disease and alleviating cardiac dysfunction caused by the disease.

The application relates to the field of biological medicine, and discloses application of a treatment target in preparation of a drug for treating heart function after myocardial infarction, and the treatment target is NR1D1. The application discloses that NR1D1 is a key target for treating heart dysfunction after myocardial infarction, and it is proved that by exciting NR1D1, the heart function can be significantly improved, the myocardial injury can be reduced, the fibrosis and cell apoptosis can be inhibited, NR1D1 plays a protection role by directly activating RABGAP1L, a "HIF-PHIs-NR1D1-RABGAP1L" signal shaft is formed, a new target and mechanism are provided for the treatment of myocardial infarction, an experimental basis is provided for a new use of Roxadustat in the protection of heart function after myocardial infarction, and the application has a good clinical application prospect.

The application relates to the field of biological medicine, and provides application of OpiCa1 mutant peptide DE-4A in antagonizing heart failure after myocardial infarction. Experiments prove that the polypeptide DE-4A can remodel myocardial calcium homeostasis by restoring RyR2 protein stability and blocking excessive activation of the CaMKII signal pathway. This mechanism effectively reduces myocardial injury and fibrosis, significantly improves ventricular remodeling and heart dysfunction after myocardial infarction, and provides new experimental evidence for the treatment of ischemic cardiomyopathy. DE-4A has the effects of improving myocardial contractile function, regulating Ca 2+ homeostasis, which may be a key link in the pharmacodynamic mechanism, and provides new experimental evidence for the treatment of ischemic heart disease.

The present invention relates to a pharmaceutical compound or a composition comprising the same, which affects Ca2 + homeostasis in cardiac cardiomyocytes of the heart by means of an active substance that modulates the process of modulating LPI metabolism and signaling in the heart by Rab8a against AS160. The pharmaceutical composition can prevent and / or treat cardiac dysfunction of human subjects or other spinal animals, especially obesity cardiomyopathy and dilated cardiomyopathy.

The invention discloses application of a substance for increasing the content and / or activity of PGAM5 protein or active fragments thereof in improving heart functions, delaying heart senescence and treating and / or preventing cardiovascular diseases. Experiments show that high-level ROS myocardial cell accumulation, increase of the overall ROS level of heart tissue, activation of cardiac inflammatory response and phenotype of premature senility are caused by specific knockout of PGAM5 from myocardial cells, and it is indicated that PGAM5 has an important effect in the aspect of maintaining the cardiac function. Meanwhile, PGAM5 is overexpressed in a naturally-aged mouse model, and the result shows that overexpressed PGAM5 of myocardial cells can regulate and control oxygen death, improve cardiac dysfunction generated in the natural aging process, reduce the proportion of high-level ROS myocardial cells, reduce the ROS level of heart tissue and reduce the fibrosis level of the aged heart. The invention provides a new thought for developing gene therapy for improving heart functions and delaying heart senescence in heart senescence and cardiovascular diseases, and has important application value.

The invention provides application of an ACLY gene medicine in preparation of a medicine for treating and preventing cardiomyopathy. The sequence of the ACLY gene is SEQ ID NO.1, and the cardiomyopathy comprises cardiac dysfunction caused by isoprenaline and thoracic aorta constriction. A cardiomyopathy drug AAV9-cTnT-ACLY taking ACLY in mitochondria as a drug target is developed by researching the relationship between ACLY and the occurrence mechanism of cardiomyopathy, the drug is based on an AAV9 adeno-associated virus vector, an ACLY gene segment is inserted into the vector, and finally animal experiments are performed to verify the effect of the drug. It is found that the high-expression mitochondrial targeting ACLY can significantly improve the expression and activity of ACLY in myocardial cells, inhibit mitochondrial protein acetylation and significantly improve the heart function of mice, and has very high clinical value.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating liver cirrhosis cardiomyopathy and a preparation method thereof, the traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 3-15g of radix aconiti lateralis preparata, 8-20g of red ginseng, 0-20g of cassia twig, 25-45g of astragalus membranaceus, 20-35g of salvia miltiorrhiza, 5-20g of turtle shell, 10-20g of radix ophiopogonis, 10-20g of poria cocos, 6-25g of rhizoma alismatis, 0-15g of curcuma zedoary, 0-20g of radix bupleuri, 10-25g of angelica sinensis, 0-25g of radix paeoniae rubra, 0-35g of pericarpium arecae, 5-15g of honey-fried licorice root and 0-25g of rhizoma zingiberis. Liver function and cardiac dysfunction of a patient with cirrhosis cardiomyopathy are improved through a multi-target synergistic effect, simultaneous treatment of liver and heart is realized, the blank of specific therapeutic drugs for cirrhosis cardiomyopathy is filled, and meanwhile, the preparation process is standardized to ensure stable drug effect.